KLK6 and ovarian carcinoma: By contrast, as a result of its upregulation in human colon cancer [30], gastric cancer [31], ovarian cancer [32] and melanoma [33], KLK6 has been identified as a potential target for pharmacologic intervention, as well as a prognostic indicator for disease progression and survival [34, 35].